Regulation of Epigenetic BET Proteins on Alzheimer’s Disease in Preclinical Models

Epigenetic regulation plays substantial roles in human pathophysiology, which provides opportunities for intervention in human disorders through targeting epigenetic pathways. Emerging evidence from both preclinical and clinical studies suggested the potential in developing therapeutics of Alzheimer’s disease (AD) by targeting epigenetic regulatory proteins. Recently there has been keen interest in the family of bromodomain (BD)‐containing BET (bromodomain and extra terminal domain) proteins, which consists of 4 protein members. All BET proteins have two BD domains, which confer significant and complex regulatory mechanisms for AD.